GlassScriptPrepare for your visit
Nicholas Argento
Endocrinology, Diabetes & Metabolism · Laurel, MD · NPI 1093781155
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$1,055,808.80
in general payments reported to CMS, 2019-2025 · $129K in 2025
The $129K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Who reported paying
General payments only, top 6 by amount.
- Dexcom, INC. $385,716.19
- Lilly USA, LLC $322,495.33
- Novo Nordisk INC $146,470.83
- Boehringer Ingelheim Pharmaceuticals, INC. $47,791.56
- Xeris Pharmaceuticals, INC. $33,792.34
- Tandem Diabetes Care, INC. $28,372.31
Drugs and devices associated with these payments
Dexcom G7 Gss (161) Mounjaro Dexcom Stelo Glucose Biosensor Ozempic Jardiance T:Slim X2 Insulin Pump With Control-Iq Rybelsus Omnipod Aquacel Ag+ Gvoke Hypopen Ilet Bionic Pancreas Tzield
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Nicholas Argento listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/4910/nicholas-argento